Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease

Journal of Nutrition, Health and Aging

Volumn 20, Issue 6, 2016, Pages 659-664

  Acena A ^a   Pello, A M ^a   Carda, R ^a   Lorenzo, O ^a   Gonzalez Casaus, M L ^b   Blanco Colio, L M ^a   Martin Ventura J L ^a   Palfy, J ^a   Orejas, M ^a   Rabago R ^a   Gonzalez Parra, E ^a   Mahillo Fernandez I ^a   Farre J ^a   Egido, J ^a   Tuñón, José ^a  

^a 28400 Madrid   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

left ventricular hypertrophy; mineral metabolism; Parathormone; stable coronary artery disease

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 23; GALECTIN 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PREVALENCE; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED;

AGED; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PARATHYROID HORMONE;

EID: 84950255624     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-015-0649-y     Document Type: Article

References (40)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322:1561–1566.
2. Kestenbaum B, Katz R, de Boer I, et al (2011) Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 58:1433–1441.
3. van Ballegooijen AJ, Snijder MB, Visser M et al (2012) Vitamin D in relation to myocardial structure and function after eight years of follow-up: the Hoorn study. Ann Nutr Metab 60:69–77.
4. Taylor EN, Curhan GC, Forman JP (2008) Parathyroid hormone and the risk of incident hypertension. J Hypertens 26:1390–1394.
5. Anderson JL, Vanwoerkom RC, Horne BD, et al (2011) Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?. Am Heart J 162:331–339.
6. Saleh FN, Schirmer H, Sundsfjord J, Jorde R (2003) Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24:2054–2060.
7. Hagström E, Hellman P, Larsson TE et al (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119:2765–2771.
8. Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503–511.
9. Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schluter KD (2009) Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res 82:77–83.
10. Tuñón J, Cristóbal C, Tarín N et al (2014) Coexistence of low vitamin d and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One 18;e95402.
11. Jovanovich A, Ix JH, Gottdiener J et al (2013) Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231:114–119.
12. Faul C, Amaral AP, Oskouei B, et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 21:4393–4408.
13. van Ballegooijen AJ, Visser M, Cotch MF et al (2013) Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab 98:2544–2552.
14. Velagaleti RS, Gona P, Levy D et al (2008) Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 118:2252–2558.
15. Tuñón J, Blanco-Colio L, Cristóbal C et al (2014) Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol 113:434–440.
16. Lang RM, Bierig M, Devereux RB et al (2005) Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463.
17. Wang L, Song Y, Manson JE et al (2012) Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 5:819–829.
18. Grandi NC, Breitling LP, Brenner H (2010) Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med 51:228–233.
19. Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG (2012) 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 32:2794–2802.
20. Karakas M, Thorand B, Zierer A, et al (2013) Low levels of serum 25-hydroxyvitamin D are associated with increased risk of myocardial infarction, especially in women: results from the MONICA/KORA Augsburg case-cohort study. J Clin Endocrinol Metab 98:272–280.
21. Siasos G, Tousoulis D, Oikonomou E, et al (2013) Vitamin D serum levels are associated with cardiovascular outcome in coronary artery disease. Int J Cardiol 168:4445–4447.
22. Palmer SC, Hayen A, Macaskill P, et al (2011) Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305:1119–1127.
23. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA (2013) Parathyroid hormone and cardiovascular disease events: A systematic review and meta-analysis of prospective studies. Am Heart J 165:655–664.
24. Ketteler M, Wolf M, Hahn K, Ritz E (2013) Phosphate: a novel cardiovascular risk factor. Eur Heart J 34:1099–1101.
25. Tuñón Fernández J, Aceña A, Tarín N, et al (2014) Abnormalities of mineral metabolism: prevalence in coronary artery disease and relationship with plasma biomarkers and lipid levels. Eur Heart J 35(Abstract Suppl):652.
26. Watson KE, Abrolat ML, Malone LL, et al (1997) Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96:1755–1760.
27. Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427–1435.
28. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC (2011) Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 161:956–62.
29. Gutiérrez OM, Januzzi JL, Isakova T, et al (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552.
30. Agarwal I, Ide N, Ix JH, et al (2014) Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 13:e000584.
31. Hu MC, Kuro-o M, Moe OW (2013) Renal and extrarenal actions of Klotho. Semin Nephrol 33:118–129.
32. Tomaschitz A, Pilz S, Ritz E, et al (2010) Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 411:1354–1360.
33. Ameri P, Canepa M, Milaneschi Y, et al (2013) Relationship between vitamin D status and left ventricular geometry in a healthy population: results from the Baltimore Longitudinal Study of Aging. J Intern Med 273:253–262.
34. Agarwal G, Nanda G, Kapoor A, et al (2013) Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy: results of a prospective case control study. Surgery 154:1394–1403.
35. Hagström E, Ingelsson E, Sundström J et al (2010) Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 12:1186–1192.
36. Levin A, Bakris GL, Molitch M, et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38.
37. van Ballegooijen AJ, Visser M, Kestenbaum B, et al (2013) Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol 111:418–424.
38. Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674–684.
39. Ratto E, Leoncini G, Viazzi F, et al (2007) C-reactive protein and target organ damage in untreated patients with primary hypertension. J Am Soc Hypertens 1:407–413.
40. Monfared A, Salari A, Kazemnezhad E, et al (2013) Association of left ventricular hypertrophy with high-sensitive C-reactive protein in hemodialysis patients. Int Urol Nephrol 45:1679–1686.